Imatinib-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases

Skeletal Radiology

Volumn 36, Issue 9, 2007, Pages 895-898

  Vanel, D ^a   Bonvalot, S ^a   Le Pechoux, C ^a   Cioffi, A ^a   Domont, J ^a   Le Cesne, A ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Bone marrow; GIST; Metastases; MRI; Necrosis

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; BONE BIOPSY; BONE MARROW BIOPSY; BONE MARROW NECROSIS; BONE METASTASIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; HUMAN; ILIAC BONE; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RECTUM CANCER; RECTUM RESECTION; BONE MARROW DISEASE; BONE TUMOR; CHEMICALLY INDUCED DISORDER; FATALITY; METASTASIS; NECROSIS; PATHOLOGY; PELVIC GIRDLE; REMISSION;

ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW DISEASES; BONE NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NECROSIS; PELVIC BONES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION;

EID: 34548038789     PISSN: 03642348     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00256-007-0344-0     Document Type: Article

References (8)

1. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11: 728-734.
2. De Mestier P, Guetz GD. Treatment of gastrointestinal stromal tumors with imatinib mesylate: A major breakthrough in the understanding of tumor-specific molecular characteristics. World J Surg 2005;29: 357-361.
3. Ray-Coquard J, Le Cesne A, Blay JY. STI571 and gastrointestinal stromal tumors. Bull Cancer 2001;88: 661-662.
4. Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep 2005;7: 307-311.
5. Padhani AR, Ollivier L. The RECIST criteria: Implications for diagnostic radiologists. Br J Radiol 2001;74: 983-986.
6. Vanel D, Albiter M, Shapeero LG, et al. Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: A prospective study of 54 patients. Eur J Radiol 2005;54: 118-123.
7. Matsue K, Takeuchi M, Koseki M, Uryu H. Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Hematol 2006;85: 542-544.
8. Tamura T, Tasaka T, Fujimoto M, Matsuhashi Y, Fukumot T, Mano S, Kuwajima M, Nagai M. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy. Haematologica 2004;89:ECR32.